An observational study in Nemaline Myopathy, sponsored by Stanford University. Not yet recruiting at 6 sites in 2 countries. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Neuromuscular Diseases with a site in United States — 29 open to participants now, 39 under way, 4 of them phase 3. Neuromuscular Diseases · United States.
Among the 120 studies in Neuromuscular Diseases with a site in United States, this one is the 27th largest by planned enrollment of the 46 observational ones that give a count, is one of 10 that started in 2025, is one of 46 observational ones, reaches primary completion later than 28 of the 38 other live ones, and was the 95th registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.
Browse Neuromuscular Diseases studies →29 of the 120 studies in Neuromuscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18–70
David Toupin · Sites in United States
Ages 6–12
University of Pennsylvania · Sites in United States
Ages 18+
Dyne Therapeutics · Sites in United States
Ages 4–18 · Men only
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.
This study: 0 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 20
First in 1984; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 48 across the 72 interventional studies, 82 across the 46 observational. Of the 77 that completed or were terminated, 28 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 120 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 1 study filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
14 of the studies in Neuromuscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT06970522Shirley Ryan AbilityLabWearable Sensors to Detect Atypical Muscle Activation in Young Infants | 2026-12-31 |
| NCT00390104Boston Children's HospitalMolecular Analysis of Patients With Neuromuscular Disease | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07223632Vanda PharmaceuticalsTreatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient | 2027-03 |
Add all 14 to your calendar (.ics) → With an account.
Among the 120 studies in Neuromuscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to establish a research network to help define the natural disease history and clinical outcome measures for Nemaline Myopathy (NM).
The long-term aim of this study is to incorporate these outcome measures into clinical trials for NM therapies. Outcome measures to be assessed will be dependent on the participant's age and functional status. Follow-up visits will be conducted either every 3 or 6 months, dependent on age, for a total of 3 years.
Participants will be identified through several sources. The primary source will be through our NM-CRN MDA care center network. Participants will also be recruited through the CMDIR and the Beggs Laboratory. Information regarding the study will be disseminated to all MDA clinics through the MDA website and via email to clinic directors. In addition, the study will advertised to families through A Foundation Building Strength, which maintains a patient information website and newsletter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in the study will have a diagnosis of Nemaline Myopathy, with either a pathogenic or likely pathogenic mutation in ACTA1 (AD) or NEB (AR). Participants can be either ambulatory or non-ambulatory and must be between the ages of 0-18.
Validate the change over 36 months using the Alberta Infant Motor Scale (AIMS) Score
The AIMS is a standardized tool used to assess a child's gross motor development in four positions: prone, supine, sitting, and standing. Percentile scores are given from 0-100, with higher percentiles representing higher motor function.
Time frame: 36 months
Validate the change over 36 months using the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
The CHOP-INTEND assesses a child's ability to move their body in a lying down position, supported sitting, and assisted rolling through 16 items.
Time frame: 36 months
Validate the change over 36 months using the Hammersmith Infant Neurological Examination Section 2 (HINE-2)
This is a 37-item measure of infant developmental motor milestones divided into the following categories: neurological examination, developmental milestones and behavioral scale, and state of consciousness. Scores for individual categories will be combined into a composite score.This will be performed in participants aged 0-24months. Scores are interpreted in relation to optimality scores and cut-off scores for the participant's age. Higher scores represented higher function.
Time frame: 36 months
Validate the change in 32-item Motor Function Measure (MFM32) Scale Score
This motor function assessment consists of 32 items organized in three dimensions: standing position and transfers, axial and limb proximal motor function, and limb distal motor function. Total scores are given between 0-100, with 0 indicating severe functional impairment and 100 indicating no functional impairment.
Time frame: 36 months
Change in Peabody Developmental Motor Scales (PDMS-3) Scale Score
This is used to measure various motor abilities in young children. Four types of normative scores are yielded: age equivalents, percentile ranks, subtest scaled scores, and composite index scores. Age equivalents are indexes of relative standing that translate subtest raw scores into motor ages. Percentiles provide the examiner with an index that is easily understood. Subtest scaled scores are based on a distribution having a mean of 10 and a standard deviation of 3. Composite indexes are based on a distribution with a mean of 100 and a standard deviation of 15. Higher scores indicate higher level of function.
Time frame: 36 months
Change in ambulation over 36 months as measured by the 10 meter walk (m/s).
This test measures the time taken for a participant to walk 10 metres as quickly and safely as possible. This will be performed in ambulatory participants aged 2 years and older.
Time frame: 36 months
Change in ambulation over 36 months as measured by the 6 Minute Walk Test
This is a measure of how far a participant can walk along a track in 6 minutes. This will be performed in ambulatory participants aged 5 years and older.
Time frame: 36 months
Change in respiratory function over 36 months as measured by spirometry, specifically the supine forced vital capacity (FVC).
This is a measure (% predicted) of the maximum amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. This will be performed in participants aged 5 years and older.
Time frame: 36 months
Change in muscle thickness of lower extremity muscles over 36 months as measured by muscle ultrasound.
This will be conducted in a subset of participants aged \>5 years.
Time frame: Baseline through month 36
Skin Biopsy (optional)
This optional outcome measure involves a one-time removal of three to four 2mm pieces of skin from one body site.
Time frame: Baseline through month 36
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Dec 2029, 59 months later.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's planned 59 months is above that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.